Release Date: 25-Jan-2025
BAT8006 is an experimental antibody-drug conjugate (ADC) developed by Bio-Thera, a biopharmaceutical company based in China. This targeted therapy is aimed at Folate Receptor-alpha (FRandalpha;), a protein that is overexpressed in various cancers, including breast and ovarian cancers. BAT8006 employs Bio-Thera’s advanced ADC platform, which features a stable cleavable linker and a potent Topoisomerase 1 inhibitor, Exatecan, as its therapeutic payload. This combination facilitates effective tumor targeting and the release of the cytotoxic agent directly within cancer cells, thereby enhancing therapeutic efficacy through a bystander effect.
Download Insight: https://www.kuickresearch.com/report-cancer-drug-conjugates-market-size
BAT8006 has demonstrated encouraging preclinical outcomes, exhibiting notable anti-tumor effects and a favorable safety profile in both in vitro and in vivo investigations. It is presently in Phase 2 clinical trials in China, targeting platinum-resistant ovarian cancer. These trials are designed to evaluate its efficacy and safety, positioning BAT8006 as a potential "best-in-class" antibody-drug conjugate (ADC) for cancers characterized by FRandalpha; overexpression.